Print Page  Close Window


Overview

Corporate Profile

Orexigen Therapeutics, Inc. is a biopharmaceutical company focused on the treatment of obesity. Orexigen’s first medicine, Contrave® (naltrexone HCl and bupropion HCl extended release), was approved in the United States in September 2014 and has become the most prescribed branded obesity medication since June 2015. In Europe the drug has been approved under the brand name Mysimba™ (naltrexone HCl/ bupropion HCl prolonged relMore >>

Stock Quote

OREX (Common Stock)
ExchangeNASDAQ (US Dollar)
Financial Status IndicatorD
Price$2.12
Change (%) Stock is Down 0.17 (7.42%)
Volume193,680
Sep 22, 2017 4:00 p.m. ET
Minimum 20 minute delay
Refresh quote

Recent News

More >>
DateTitle 
09/13/17Orexigen Therapeutics to Provide Business Update at the 2017 Cantor Fitzgerald Global Healthcare ConferencePrinter Friendly Version
08/29/17Orexigen Therapeutics to Speak at Upcoming Investor ConferencesPrinter Friendly Version
08/08/17Orexigen Therapeutics Announces Second Quarter 2017 Financial ResultsPrinter Friendly Version
08/07/17Orexigen Therapeutics Announces Commercialization and Distributorship Arrangement with Cheplapharm Arzneimittel GmbH for Mysimba™ in Germany, France and AustriaPrinter Friendly Version

Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.